CADENCE PHARMACEUTICALS INC 4
4 · CADENCE PHARMACEUTICALS INC · Filed Nov 18, 2013
Insider Transaction Report
Form 4
Byrd Scott A.
SVP, Chief Commercial Officer
Transactions
- Exercise/Conversion
stock option (right to buy)
2013-11-15−10,416→ 78,126 totalExercise: $3.51Exp: 2022-03-14→ common stock (10,416 underlying) - Exercise/Conversion
common stock
2013-11-15$3.51/sh+10,416$36,560→ 12,416 total - Sale
common stock
2013-11-15$8.00/sh−10,416$83,328→ 2,000 total
Footnotes (3)
- [F1]The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 7, 2013.
- [F2]25% of the 125,000 shares of common stock originally subject to the option vested on 3/14/2013, and 1/48th of the remaining number of shares of common stock subject to the option vest on the first day of each full month thereafter.
- [F3]Not applicable to this transaction.